1.275

5.20% -0.07

Biodesix Inc (BDSX)

Overview News Price History Option Chain Financials Discussions Forecast

Biodesix Inc stock is traded at $1.275, with a volume of 582.24K. It is down -5.20% in the last 24 hours and down -20.81% over the past month. Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Previous Close:

$1.345

Open:

$1.33

24h Volume:

582.24K

Relative Volume:

2.45

Market Cap:

$188.38M

Revenue:

$49.09M

Net Income/Loss:

$-52.15M

P/E Ratio:

-1.1591

EPS:

-1.1

Net Cash Flow:

$-45.93M

1W Performance:

-9.57%

1M Performance:

-20.81%

6M Performance:

-19.05%

1Y Performance:

-10.84%

1-Day Range:

$1.27

$1.33

1-Week Range:

$1.27

$1.45

52-Week Range:

$1.15

$2.21

Biodesix Inc Stock (BDSX) Company Profile

Name

Biodesix Inc

Sector

Healthcare (1200)

Industry

Diagnostics & Research (57)

Phone

303-417-0500

Address

919 WEST DILLON ROAD, LOUISVILLE

Employee

217

Twitter

Next Earnings Date

2024-11-27

Latest SEC Filings

BDSX's Discussions on Twitter

Compare BDSX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BDSX	1.27	188.38M	49.09M	-52.15M	-45.93M	-1.10
TMO	501.28	192.46B	42.37B	6.14B	7.78B	15.26
DHR	229.63	165.90B	23.74B	3.89B	4.98B	7.93
A	126.69	36.48B	6.50B	1.41B	1.42B	3.82
IDXX	421.56	34.55B	3.84B	866.24M	792.60M	9.80
IQV	190.64	34.31B	15.32B	1.41B	1.96B	5.95

Biodesix Inc Stock (BDSX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-17-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-23-20	Initiated	BTIG Research	Buy
Nov-23-20	Initiated	Canaccord Genuity	Buy
Nov-23-20	Initiated	Morgan Stanley	Overweight
Nov-23-20	Initiated	William Blair	Outperform

Biodesix Inc Stock (BDSX) Latest News

Nov 15, 2024

Biodesix chief commercial officer sells shares worth $644 - Investing.com India

Nov 15, 2024

Nov 14, 2024

Biodesix CEO Scott Hutton sells $5,219 in stock - Investing.com India

Nov 14, 2024

Biodesix CEO Scott Hutton sells $5,219 in stock By Investing.com - Investing.com Australia

Nov 14, 2024

Nov 13, 2024

Biodesix's chief development officer sells shares for $595 - Investing.com

Nov 13, 2024

Biodesix CFO Robin Harper Cowie sells $1,355 in stock - Investing.com

Nov 13, 2024

Biodesix chief commercial officer sells shares worth $644 By Investing.com - Investing.com UK

Nov 13, 2024

Biodesix's chief development officer sells shares for $595 By Investing.com - Investing.com UK

Nov 13, 2024

Biodesix chairman John Patience acquires $103,710 in stock - Investing.com India

Nov 07, 2024

Biodesix chairman John Patience acquires $103,710 in stock By Investing.com - Investing.com Australia

Nov 07, 2024

Nov 06, 2024

Biodesix director Jack Schuler buys $136k in stock - Investing.com

Nov 06, 2024

Biodesix director Kennedy Lawrence T. Jr. acquires $97,068 in stock - Investing.com

Nov 06, 2024

Biodesix director Matthew Strobeck acquires $55,915 in stock - Investing.com

Nov 06, 2024

Biodesix director Massarany buys $30,865 in common stock - Investing.com India

Nov 06, 2024

Biodesix director Kennedy Lawrence T. Jr. acquires $97,068 in stock By Investing.com - Investing.com Nigeria

Nov 06, 2024

Nov 03, 2024

Earnings call: Biodesix sees strong growth in Q3 with $18.2M revenue - Investing.com India

Nov 03, 2024

Brokerages Set Biodesix, Inc. (NASDAQ:BDSX) PT at $3.06 - MarketBeat

Nov 03, 2024

Biodesix, Inc. (NASDAQ:BDSX) Receives Consensus Rating of “Buy” from Analysts - Defense World

Nov 03, 2024

Nov 02, 2024

Biodesix (NASDAQ:BDSX) Releases Quarterly Earnings Results, Meets Expectations - MarketBeat

Nov 02, 2024

Biodesix reports Q3 EPS (7c), consensus (7c) - MSN

Nov 02, 2024

Biodesix Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 02, 2024